文献速递临床试验与 GCP新药、器械与细胞基因治疗研发

COVIT-TRIAL:高风险老年COVID-19患者高剂量维生素D补充的随机对照试验方案

COvid-19 and high-dose VITamin D supplementation TRIAL in high-risk older patients (COVIT-TRIAL): study protocol for a randomized controlled trial.
PubMed 文献 · Trials · 2020-12-28

主要结局为入组后14天内全因死亡率,次要结局包括WHO临床改善 ordinal 量表(OSCI)评分变化及安全性比较。

要点

  • 高危老年COVID-19患者单次口服高剂量胆钙化醇对比标准剂量,主要终点为14天全因死亡率。
  • 纳入标准包括年龄≥75岁或室内空气SpO2≤94%或PaO2/FiO2≤300 mmHg等恶化风险因素。
  • 高剂量组为入组当日一次性口服2瓶200,000 IU胆钙化醇,标准剂量组为50,000 IU。

核心结论

  • 高剂量维生素D补充可能改善高风险老年COVID-19患者的预后,但本方案尚未报告疗效结果。

研究设计与样本

  • 纳入标准:RT-PCR和/或胸部CT确诊3天内,且至少一项恶化风险因素(年龄≥75岁,或室内空气SpO2≤94%,或PaO2/FiO2≤300 mmHg)。
  • 排除标准:对维生素D补充有禁忌,或前一个月内接受>800 IU/天维生素D补充。
  • 随机分组:高剂量胆钙化醇(入组当日一次性口服2瓶200,000 IU)vs 标准剂量(入组当日口服1瓶50,000 IU)。
  • 随访28天,评估基线、第14天和第28天的结局,以及基线和第7天的血清25(OH)D、肌酐、钙和白蛋白浓度。

主要发现

  • 主要结局为入组后14天内全因死亡率。
  • 次要结局包括WHO COVID-19临床改善 ordinal 量表(OSCI)评分变化及组间安全性比较。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: With the lack of effective therapy, chemoprevention, and vaccination against SARS-CoV-2, focusing on the immediate repurposing of existing drugs gives hope of curbing the COVID-19 pandemic. A recent unbiased genomics-guided tracing of the SARS-CoV-2 targets in human cells identified vitamin D among the three top-scoring molecules manifesting potential infection mitigation patterns. Growing pre-clinical and epidemiological observational data support this assumption. We hypothesized that vitamin D supplementation may improve the prognosis of COVID-19. The aim of this trial is to compare the effect of a single oral high dose of cholecalciferol versus a single oral standard dose on all-cause 14-day mortality rate in COVID-19 older adults at higher risk of worsening. METHODS: The COVIT-TRIAL study is an open-label, multicenter, randomized controlled superiority trial. Patients aged ≥ 65 years with COVID-19 (diagnosed within the preceding 3 days with RT-PCR and/or chest CT scan) and at least one worsening risk factor at the time of inclusion (i.e., age ≥ 75 years, or SpO2 ≤ 94% in room air, or PaO2/FiO2 ≤ 300 mmHg), having no contraindications to vitamin D supplementation, and having received no vitamin D supplementation > 800 IU/day during the preceding month are recruited. Participants are randomized either to high-dose cholecalciferol (two 200,000 IU drinking vials at once on the day of inclusion) or to standard-dose cholecalciferol (one 50,000 IU drinking vial on the day of inclusion). Two hundred sixty participants are recruited and followed up for 28 days. The primary outcome measure is all-cause mortality within 14 days of inclusion. Secondary outcomes are the score changes on the World Health Organization Ordinal Scale for Clinical Improvement (OSCI) scale for COVID-19, and the between-group comparison of safety. These outcomes are assessed at baseline, day 14, and day 28, together with the serum concentrations of 25(OH)D, creatinine, calcium, and albumin at baseline and day 7. DISCUSSION: COVIT-TRIAL is to our knowledge the first randomized controlled trial testing the effect of vitamin D supplementation on the prognosis of COVID-19 in high-risk older patients. High-dose vitamin D supplementation may be an effective, well-tolerated, and easily and immediately accessible treatment for COVID-19, the incidence of which increases dramatically and for which there are currently no scientifically validated treatments. TRIAL REGISTRATION: ClinicalTrials.gov NCT04344041 . Registered on 14 April 2020 TRIAL STATUS: Recruiting. Recruitment is expected to be completed in April 2021.

来源:Trials,查看原文。版权归原作者所有。

引用

  1. Annweiler C, Beaudenon M, Gautier J, et al. COvid-19 and high-dose VITamin D supplementation TRIAL in high-risk older patients (COVIT-TRIAL): study protocol for a randomized controlled trial. Trials. 2020. PMID: 33371905. doi:10.1186/s13063-020-04928-5

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。